Artax Biopharma is a clinical-stage biotechnology company transforming T Cell-mediated disease treatment by developing innovative small molecules that modulate the immune system. Artax science holds broad potential to treat T Cell-mediated diseases such as autoimmune diseases; induced T cell pathologies (such as acute graft-versus-host disease and immune-oncology treatment-related adverse events); and T Cell malignancies, while simultaneously allowing the body to fight foreign pathogens.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/11/22 | $26,000,000 |
Advent Life Sciences Columbus Ventures Eli Lilly and Company Sound Bioventures Termeer Family Office | undisclosed |
